Globus Medical Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Dan Scavilla
Algemeen directeur
US$4.6m
Totale compensatie
| Percentage CEO-salaris | 10.2% |
| Dienstverband CEO | 2.6yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 5.6yrs |
| Gemiddelde ambtstermijn bestuur | 5.5yrs |
Recente managementupdates
Recent updates
Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04
Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$92m |
| Jun 30 2024 | n/a | n/a | US$41m |
| Mar 31 2024 | n/a | n/a | US$67m |
| Dec 31 2023 | US$5m | US$464k | US$123m |
| Sep 30 2023 | n/a | n/a | US$158m |
| Jun 30 2023 | n/a | n/a | US$204m |
| Mar 31 2023 | n/a | n/a | US$201m |
| Dec 31 2022 | US$4m | US$437k | US$190m |
| Sep 30 2022 | n/a | n/a | US$155m |
| Jun 30 2022 | n/a | n/a | US$155m |
| Mar 31 2022 | n/a | n/a | US$142m |
| Dec 31 2021 | US$2m | US$396k | US$149m |
| Sep 30 2021 | n/a | n/a | US$187m |
| Jun 30 2021 | n/a | n/a | US$184m |
| Mar 31 2021 | n/a | n/a | US$122m |
| Dec 31 2020 | US$2m | US$384k | US$102m |
| Sep 30 2020 | n/a | n/a | US$95m |
| Jun 30 2020 | n/a | n/a | US$89m |
| Mar 31 2020 | n/a | n/a | US$148m |
| Dec 31 2019 | US$2m | US$366k | US$155m |
| Sep 30 2019 | n/a | n/a | US$146m |
| Jun 30 2019 | n/a | n/a | US$143m |
| Mar 31 2019 | n/a | n/a | US$150m |
| Dec 31 2018 | US$2m | US$355k | US$156m |
| Sep 30 2018 | n/a | n/a | US$144m |
| Jun 30 2018 | n/a | n/a | US$134m |
| Mar 31 2018 | n/a | n/a | US$118m |
| Dec 31 2017 | US$1m | US$345k | US$107m |
Compensatie versus markt: De totale vergoeding ($USD 4.56M ) Dan } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Dan Scavilla (59 yo)
2.6yrs
Tenure
US$4,564,374
Compensatie
Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.8yrs | US$3.22m | 16.44% $ 1.9b | |
| President | 2.6yrs | US$4.56m | geen gegevens | |
| CFO & COO | 5.3yrs | US$2.06m | 0% $ 0 | |
| Senior VP | 5.9yrs | US$1.64m | 0% $ 0 | |
| Senior Vice President of Business Development & Investor Relations | no data | geen gegevens | geen gegevens |
5.6yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GMED is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.8yrs | US$3.22m | 16.44% $ 1.9b | |
| President | 2.6yrs | US$4.56m | geen gegevens | |
| Independent Director | 13.3yrs | US$490.69k | 0.032% $ 3.6m | |
| Independent Director | 1.2yrs | US$276.27k | 0.011% $ 1.3m | |
| Independent Director | 5.5yrs | US$470.69k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$478.19k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$278.15k | 0.018% $ 2.0m | |
| Independent Director | 4.9yrs | US$470.69k | 0.0015% $ 166.7k | |
| Independent Director | 21.7yrs | US$468.19k | 0.53% $ 60.1m | |
| Independent Director | 1.2yrs | US$278.77k | 0.012% $ 1.4m | |
| Independent Director | 13.6yrs | US$478.19k | 0% $ 0 |
5.5yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).